Compare

BridgeBio Pharma, Inc. vs Mirum Pharmaceuticals, Inc. vs Nature's Sunshine Products Inc vs HUTCHMED (China) Ltd

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	BridgeBio Pharma, Inc. BBIO	Mirum Pharmaceuticals, Inc. MIRM	Nature's Sunshine Products Inc NATR	HUTCHMED (China) Ltd HCM
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$502.08M	$521.31M	$480.14M	$548.51M
Revenue growth (YoY)	+126.3%	+54.7%	+5.7%	-13.0%
Gross margin	n/a	n/a	72.4%	38.7% (computed)
Operating margin	-104.2%	-4.2%	5.2%	-7.1%
Net margin	-146.0%	-4.5%	4.3%	83.3%
Net income	-$732.94M	-$23.36M	$20.45M	$456.91M
EPS (Diluted)	-$3.78	-$0.47	$1.06	$0.52
Operating cash flow	-$445.91M	$55.83M	$35.32M	-$64.66M
Free cash flow	-$447.01M	$54.87M	$28.84M	-$78.81M
Cash & equivalents	$570.12M	$296.68M	$93.89M	$71.33M
Total assets	$936.02M	$842.81M	$261.15M	$1.75B
Total liabilities	$3.01B	$528.12M	$99.59M	$501.83M
Shareholders' equity	-$2.09B	$314.69M	$161.55M	$1.25B
Return on year-end equity	n/a	-7.4%	12.7%	36.5%
Shares outstanding	194.77M	51.90M	17.51M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	BridgeBio Pharma, Inc.	Mirum Pharmaceuticals, Inc.	Nature's Sunshine Products Inc	HUTCHMED (China) Ltd
Latest	$502.08M Ended 2025-12-31	$521.31M Ended 2025-12-31	$480.14M Ended 2025-12-31	$548.51M Ended 2025-12-31
1 year earlier	$221.90M Ended 2024-12-31	$336.89M Ended 2024-12-31	$454.36M Ended 2024-12-31	$630.20M Ended 2024-12-31
2 years earlier	$9.30M Ended 2023-12-31	$186.37M Ended 2023-12-31	$445.32M Ended 2023-12-31	$838.00M Ended 2023-12-31
3 years earlier	$77.65M Ended 2022-12-31	$77.06M Ended 2022-12-31	$421.91M Ended 2022-12-31	$426.41M Ended 2022-12-31
4 years earlier	$69.72M Ended 2021-12-31	$19.14M Ended 2021-12-31	$444.08M Ended 2021-12-31	$356.13M Ended 2021-12-31